Intelligence · Clinical Development
Pipeline search results
Programs matching “treatment” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 270 pipeline programs matching "treatment" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Recommended treatment schedule
Prime Medicine
COVID-19
1 trial -
Reducing Antibiotics treatment duration
United Therapeutics Europe Ltd
Ventilator Associated Pneumonia
1 trial -
Rukobia 600 mg prolonged-release tablets
ViiV Healthcare Pty Ltd
Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1
1 trial -
Solution de chlorure de sodium à 0 for Adult Patients kidney transplan…
Pari Pharma GmbH
Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)
1 trial -
Standard of Care Treatment
Kyverna Therapeutics
Myasthenia Gravis
1 trial -
Standard treatment: Control arm
United Therapeutics Europe Ltd
Cervical Carcinoma
1 trial -
TILD-19-12
Lacuna Pharma Pty Ltd
Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis
1 trial -
Treatment as Usual (TAU)
BRIGHT MINDS BIOSCIENCES INC.
Drug Addiction
1 trial -
Treatment group
United Therapeutics Europe Ltd
Post Operative Surgical Site Infection
1 trial -
Treatment of TongBi Capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Knee Osteoarthritis
1 trial -
Trulicity 0.75 mg solution for injection in pre-filled pen
The George Institute
Preventive treatment of post-kidney transplant diabetes
1 trial -
UC-0107/1718
Ningbo Cancer Hospital
Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line
1 trial -
UC-GTG-2301
Ningbo Cancer Hospital
Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)
1 trial -
UC-IMM-2101
Ningbo Cancer Hospital
Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).
1 trial -
Vortioxetine
Takeda
Treatment Outcome
1 trial -
XPORT-MF-034
Karyopharm Therapeutics Inc
Treatment naïve patients with MF
1 trial -
ZOSTER ICO-N-2018-14
CERO THERAPEUTICS HOLDINGS, INC.
Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy
1 trial -
201
Y-Mabs Therapeutics A/S
Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow
1 trial -
2022/3418 INDIGO
The George Institute
Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.
1 trial -
2023/3668
The George Institute
Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.
1 trial -
2025-SR-813
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
299AR201
Biogen
Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants
1 trial -
514G3 (2 mg/kg) plus standard IV antibiotic treatment
XBiotech Germany GmbH
Staphylococcus Aureus Bacteremia
1 trial -
8951-CL-5201
Astellas Pharma GmbH
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.